A Phase I/II Evaluation of Stavudine (d4T) in Children With Human Immunodeficiency Virus Infection
1 Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston
2 Bristrol-Myers Squibb Company, Syracuse, NY and Wallingford, CT
3 Department of Pediatrics, University of Soutern California and Children's Hospital Los Angeles, Los Angeles
4 Department of Pediatrics, University of Southern California and Children's Hospital Los Angeles, Los Angeles
Objectives. To determine the pharmacokinetic properties, tolerance, safety, and preliminary activity of stavudine in human immunodeficiency virus (HIV)-infected children.
Design. Phase I/II, open and dose-ranging (0.125 to 4 mg/kg/day in two divided doses).
Patients. Thirty-seven HIV-infected children (median age, 5.5 years; range, 7 months to 15 years) with a median CD4+ lymphocyte count at baseline of 242 cells/µL (range 2 to 2290 cells/µL). Thirty children had symptomatic HIV disease at entry; seven had HIV-related immunosuppression alone. Twenty-nine subjects had a history of prior zidovudine (ZDV) therapy.
Results. As compared with adults receiving the same weight-adjusted doses, the children we studied had lower maximum observed stavudine plasma concentrations (CMAX) and area under the plasma concentration versus time curves (AUC), and more rapid stavudine elimination. The absolute oral bioavailability of the drug ranged from 61% to 78%. There was no plasma accumulation of the drug between day 1 and week 12. Week 12 cerebrospinal fluid stavudine concentrations in seven subjects, obtained approximately 2 to 3 hours after oral doses, ranged from 16% to 97% of concomitant plasma concentrations.
Stavudine was well-tolerated and there were no dose-related clinical or laboratory adverse events. One subject with baseline neurologic abnormalities experienced a transient episode of apparent pain or discomfort in her fingers, possibly related to stavudine. All other adverse events were attributed to underlying disease. Stavudine activity, measured indirectly by CD4+ lymphocyte count and serum p24 antigen concentration changes, was observed in some subjects. Progression of HIV disease and survival correlated with prior ZDV therapy, HIV disease classification, baseline CD4+ lymphocyte count, and weight growth velocity.
Conclusions. Stavudine appears to hold promise for the treatment of HIV infection in children. Its pharmacokinetic properties are consistent and predictable, and it appears to be remarkably well-tolerated and safe. Although our study was not designed to assess the drug's efficacy, preliminary clinical and laboratory evidence of activity was observed.
Submitted on July 12, 1994Accepted on November 7, 1994
This article has been cited by other articles:
 |
|
 |
|
  I. Shah Adverse Effects of Antiretroviral Therapy in HIV-1 Infected Children J Trop Pediatr, August 1, 2006; 52(4): 244 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hazra, F. M. Balis, A. N. Tullio, E. DeCarlo, C. J. Worrell, S. M. Steinberg, J. F. Flaherty, K. Yale, M. Poblenz, B. P. Kearney, et al. Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children Antimicrob. Agents Chemother., January 1, 2004; 48(1): 124 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rongkavilit, P. Thaithumyanon, T. Chuenyam, B. D. Damle, S. Limpongsanurak, C. Boonrod, A. Srigritsanapol, E. A. M. Hassink, R. M. W. Hoetelmans, D. A. Cooper, et al. Pharmacokinetics of Stavudine and Didanosine Coadministered with Nelfinavir in Human Immunodeficiency Virus-Exposed Neonates Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3585 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul, M. W. Kline, J. A. Church, and L. M. Dunkle Determination of Dosing Guidelines for Stavudine (2',3'-Didehydro-3'-Deoxythymidine) in Children with Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., March 1, 2001; 45(3): 758 - 763. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Sáez-Llorens, R. P. Nelson Jr, P. Emmanuel, A. Wiznia, C. Mitchell, J. A. Church, J. Sleasman, R. Van Dyke, C. G. Richardson, A. Cutrell, et al. A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children Pediatrics, January 1, 2001; 107(1): 4e - 4. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Grasela, R. R. Stoltz, M. Barry, M. Bone, B. Mangold, P. O'Grady, R. Raymond, and S. J. Haworth Pharmacokinetics of Single-Dose Oral Stavudine in Subjects with Renal Impairment and in Subjects Requiring Hemodialysis Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2149 - 2153. [Abstract] [Full Text]
|
|
|
|
|
|
C. V. Fletcher, R. C. Brundage, R. P. Remmel, L. M. Page, D. Weller, N. R. Calles, C. Simon, and M. W. Kline Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy Antimicrob. Agents Chemother., April 1, 2000; 44(4): 1029 - 1034. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. T. Shearer, M. W. Kline, S. L. Abramson, T. Fenton, S. E. Starr, and S. D. Douglas Recombinant Human Gamma Interferon in Human Immunodeficiency Virus-Infected Children: Safety, CD4+-Lymphocyte Count, Viral Load, and Neutrophil Function (AIDS Clinical Trials Group Protocol 211) Clin. Vaccine Immunol., May 1, 1999; 6(3): 311 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Kline, R. B. Van Dyke, J. C. Lindsey, M. Gwynne, M. Culnane, C. Diaz, R. Yogev, R. E. McKinney Jr, E. J. Abrams, L. M. Mofenson, et al. Combination Therapy With Stavudine (d4T) Plus Didanosine (ddI) in Children With Human Immunodeficiency Virus Infection Pediatrics, May 1, 1999; 103(5): 62e - 62. [Abstract] [Full Text]
|
|
|
|
|
|
M. W. Kline, S. Blanchard, C. V. Fletcher, J. L. Shenep, R. E. McKinney Jr, R. C. Brundage, M. Culnane, R. B. Van Dyke, W. M. Dankner, A. Kovacs, et al. A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection Pediatrics, April 1, 1999; 103(4): 47e - 47. [Abstract] [Full Text]
|
|
|
|
|
|
W. Hughes, J. A. McDowell, J. Shenep, P. Flynn, M. W. Kline, R. Yogev, W. Symonds, Y. Lou, and S. Hetherington Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children Antimicrob. Agents Chemother., March 1, 1999; 43(3): 609 - 615. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kaul, B. Christofalo, R. H. Raymond, M. B. Stewart, and C. M. Macleod Effect of Food on the Bioavailability of Stavudine in Subjects with Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2295 - 2298. [Abstract] [Full Text]
|
|
|
|
|
|
M. W. Kline, R. B. Van Dyke, J. C. Lindsey, M. Gwynne, M. Culnane, R. E. McKinney Jr, S. Nichols, W. G. Mitchell, R. Yogev, N. Hutcheon, et al. A Randomized Comparative Trial of Stavudine (d4T) Versus Zidovudine (ZDV, AZT) in Children With Human Immunodeficiency Virus Infection Pediatrics, February 1, 1998; 101(2): 214 - 220. [Abstract] [Full Text] [PDF]
|
|
